China Resources Pharmaceutical Group Limited
CRPGF
$0.5414
$0.54140.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.97B | 9.02B | 8.88B | 8.96B | 8.44B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.97B | 9.02B | 8.88B | 8.96B | 8.44B |
| Cost of Revenue | 7.60B | 7.64B | 7.43B | 7.50B | 7.15B |
| Gross Profit | 1.37B | 1.38B | 1.45B | 1.46B | 1.29B |
| SG&A Expenses | 982.18M | 986.93M | 857.94M | 865.37M | 912.15M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 78.95M | 79.33M | 69.88M | 70.48M | 93.69M |
| Total Operating Expenses | 8.66B | 8.70B | 8.36B | 8.43B | 8.16B |
| Operating Income | 312.02M | 313.53M | 517.56M | 522.04M | 280.59M |
| Income Before Tax | 269.96M | 271.26M | 486.50M | 490.72M | 249.09M |
| Income Tax Expenses | 70.98M | 71.32M | 103.95M | 104.85M | 58.94M |
| Earnings from Continuing Operations | 198.98M | 199.94M | 382.55M | 385.87M | 190.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -147.12M | -147.83M | -202.70M | -204.46M | -108.95M |
| Net Income | 51.86M | 52.11M | 179.85M | 181.41M | 81.20M |
| EBIT | 312.02M | 313.53M | 517.56M | 522.04M | 280.59M |
| EBITDA | 406.75M | 408.72M | 606.57M | 611.83M | 373.76M |
| EPS Basic | 0.01 | 0.01 | 0.03 | 0.03 | 0.01 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| EPS Diluted | 0.01 | 0.01 | 0.03 | 0.03 | 0.01 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 |
| Average Basic Shares Outstanding | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B |
| Average Diluted Shares Outstanding | 6.28B | 6.28B | 6.28B | 6.28B | 6.28B |
| Dividend Per Share | 0.00 | 0.00 | 0.01 | 0.01 | -- |
| Payout Ratio | 199.58% | 199.58% | -- | -- | 75.05% |